|Videos|September 18, 2015
Multidisciplinary Care for Prostate Cancer
Advertisement
Episodes in this series
Advertisement
Related to this article
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.
Advertisement
Advertisement
Trending on CURE
1
What New KRAS Drug Data From ESMO 2026 Mean for Patients
2
Top 5 Takeaways From ESMO 2026 That Patients Should Know
3
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
4
FDA Approves Talzenna Plus Xtandi in Hormone-Sensitive Prostate Cancer
5